

DIRECTORS' REMUNERATION REPORT CONTINUED

DIRECTORS' INTERESTS IN SHARES

Beneficial interests

The table below shows the interests at 31 December 2007 or on the date of resignation (if earlier) of the persons who on that date were Directors (including the interests of their Connected Persons, as such term is defined in the Companies Act 2006) in shares and debentures of AstraZeneca PLC. All such interests were beneficial except as otherwise stated. However, interests in Ordinary Shares or American Depositary Shares (ADSs) that are the subject of awards under the AstraZeneca Performance Share Plan, the AstraZeneca Deferred Bonus Plan or the AstraZeneca US Executive Performance Share Plan discussed elsewhere, are not included in the table below but are shown on pages 111 and 112. None of the Directors has a beneficial interest in the shares of any of the Company's subsidiaries. Between 31 December 2007 and 31 January 2008 there was no change in the interests in shares and debentures shown in the table below, with the exception of John Patterson who acquired a further 625 Ordinary Shares following the exercise of an option under the AstraZeneca Savings Related Share Option Plan.

Director	Beneficial interest in Ordinary Shares at 1 Jan 2007 or appointment date	Change to beneficial interest	Beneficial interest in Ordinary Shares at 31 Dec 2007 or resignation date
Louis Schweitzer	4,000	–	4,000
David Brennan	111,788	3,856	115,644
John Patterson	8,015	–	8,015
Simon Lowth ¹	–	850	850
John Buchanan	2,500	–	2,500
Jane Henney	500	–	500
Michele Hooper	500	–	500
Håkan Mogren	62,164	–	62,164
Nancy Rothwell	500	–	500
John Varley	500	–	500
Marcus Wallenberg	67,264	–	67,264
Bo Angelin ²	–	500	500
Former Directors			
Jonathan Symonds ³	11,527	–	11,527
Peter Bonfield ⁴	500	–	500
Joe Jimenez ⁵	500	–	500
Erna Möller ⁴	2,718	–	2,718

¹ Part year only as appointed Director on 5 November 2007.

² Part year only as appointed Director on 25 July 2007.

³ Part year only as ceased to be Director on 31 July 2007.

⁴ Part year only as ceased to be Director on 26 April 2007.

⁵ Part year only as ceased to be Director on 12 April 2007.

Unitised stock plans

David Brennan, in common with other participating executives in the US, has interests awarded to him prior to becoming Group CEO in the following: the AstraZeneca Executive Deferral Plan, the AstraZeneca Executive Deferred Compensation Plan and the AstraZeneca Savings and Security Plan. These are unitised stock plans into which the value of certain previous share incentive awards has been deferred (and are not incentive awards in their own right). Participants hold units in each plan, which represents a long-term equity interest in the Company. A unit comprises part cash and part ADSs. The overall unit value can be determined daily by taking the market value of the underlying ADSs and adding the cash position. The ADSs held within these units carry both voting and dividend rights. David Brennan is deemed to have a notional interest in these ADSs, calculated by reference to the fund value and the closing price of ADSs. Therefore, the number of ADSs in which a notional interest arises can vary daily as a consequence of stock price movements.

Unitised stock plan	ADSs held at 1 Jan 2007	Net ADSs acquired/(disposed) during 2007	ADSs held at 31 Dec 2007
AstraZeneca Executive Deferral Plan	76,071	(12,282)	63,789
AstraZeneca Executive Deferred Compensation Plan	29,103	1,279	30,382
AstraZeneca Savings and Security Plan	6,456	527	6,983

No Director or senior executive beneficially owns, or has options over, 1% or more of the outstanding shares of the Company, nor do they have different voting rights to other shareholders.

AstraZeneca Performance Share Plan

The interests of Directors and former Directors at 31 December 2007, or on the date of resignation (if earlier), in shares that are the subject of Awards under the AstraZeneca Performance Share Plan are not included in the table on the previous page but are shown below:

Award	Numbers of shares	Award price	Grant date ¹	Vesting date ¹	Performance period ¹
David Brennan					
2006 Award	73,109	2975p	24.03.06	24.03.09	01.01.06 – 31.12.08
2006 Award	19,092	2848p	19.05.06	19.05.09	01.01.06 – 31.12.08
Total at 1 Jan 2007	92,201				
2007 Award	107,051	2744p	30.03.07	30.03.10	01.01.07 – 31.12.09
Total at 31 Dec 2007	199,252				
John Patterson					
2005 Award	41,945	2241p	29.06.05	29.06.08	01.01.05 – 31.12.07
2006 Award	32,319	2975p	24.03.06	24.03.09	01.01.06 – 31.12.08
Total at 1 Jan 2007	74,264				
2007 Award	36,785	2744p	30.03.07	30.03.10	01.01.07 – 31.12.09
Total at 31 Dec 2007	111,049				
Simon Lowth					
Total at 5 Nov 2007	–				
2007 Award	15,554	2210p	16.11.07	16.11.10	01.01.07 – 31.12.09
Total at 31 Dec 2007	15,554				
Jonathan Symonds					
2005 Award	47,723	2241p	29.06.05	29.06.08	01.01.05 – 31.12.07
2006 Award	41,646	2975p	24.03.06	24.03.09	01.01.06 – 31.12.08
Total at 1 Jan 2007	89,369				
2007 Award	50,291	2744p	30.03.07	30.03.10	01.01.07 – 31.12.09
Total at 31 Jul 2007	139,660 ²				
Tom McKillop ³					
2005 Award	104,417	2241p	29.06.05	29.06.08	01.01.05 – 31.12.07
Total at 1 Jan 2007	104,417				
Total at 31 Dec 2007	104,417 ⁴				

¹ UK date convention applies.

² This represents the balance as at 31 July 2007, the date of Jonathan Symonds' resignation. In accordance with the plan rules, all Awards lapsed upon his resignation from the Company.

³ Ceased to be a Director on 31 December 2005.

⁴ To be pro-rated as described on page 74 of the 2005 Directors' Remuneration Report.

US Executive Performance Share Plan

The interests of David Brennan at 31 December 2007 in ADSs of AstraZeneca PLC that are the subject of awards under the AstraZeneca US Executive Performance Share Plan (established in 2000) are not included in the above tables but are shown below. One ADS equals one Ordinary Share. The number of ADSs to which David Brennan may become unconditionally entitled on the vesting date will be determined by reference to AstraZeneca's total shareholder return compared with that of other companies in the US Pharmaceutical Human Resources Association over the three year performance period from the date of first award.

Award	Number of ADSs	Award price	Grant date ¹	Vesting date ¹	Performance period ¹
David Brennan					
2004 Award	28,826	\$46.63	26.03.04	26.03.07	01.01.04 – 31.12.06
2005 Award	27,877	\$40.35	24.03.05	24.03.08	01.01.05 – 31.12.07
Total at 1 Jan 2007	56,703				
Vesting of 2004 Award	(15,566) ²				
Lapse of 2004 Award	(13,260)				
Total at 31 Dec 2007	27,877				

¹ UK date convention applies.

² Vesting of 2004 Award was paid out in the form of ADSs. The ADS price on the vesting date was \$54.73.

DIRECTORS' REMUNERATION REPORT CONTINUED

Deferred Bonus Plan

There is a requirement for SET members, including the Executive Directors, to defer a proportion of their bonus and to use it to acquire Ordinary Shares in the Company purchased on the market at the prevailing market price for a period of three years from the date on which the shares were first acquired. The proportion currently deferred into Ordinary Shares is one third of the pre-tax bonus for Executive Directors and one sixth for all other SET members. The interests of Directors and former Directors at 31 December 2007, or on the date of resignation (if earlier), in Ordinary Shares that are the subject of awards under these arrangements are not included in the table on the previous page but are shown below:

Award	Number of shares	Award price	Grant date ¹	Vesting date ¹
David Brennan 2006 Award	6,352	2639p	24.02.06	24.02.09
Total at 1 Jan 2007	6,352			
2007 Award	12,014	2911p	23.02.07	23.02.10
Total at 31 Dec 2007	18,366			
John Patterson 2006 Award	6,623	2639p	24.02.06	24.02.09
Total at 1 Jan 2007	6,623			
2007 Award	5,600	2911p	23.02.07	23.02.10
Total at 31 Dec 2007	12,223			
Jonathan Symonds 2006 Award	7,534	2639p	24.02.06	24.02.09
Total at 1 Jan 2007	7,534			
2007 Award	6,491	2911p	23.02.07	23.02.10
Total at 31 Jul 2007	14,025 ²			

¹ UK date convention applies.

² This represents the balance as at 31 July 2007, the date of Jonathan Symonds' resignation. In accordance with the plan rules, all Awards lapsed upon his resignation from the Company.